Halicin

Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt kinase[1][2].

Product Specifications

CAS Number

[40045-50-9]

Product Name Alternative

SU3327

UNSPSC

12352005

Hazard Statement

H315, H319

Target

JNK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/halicin.html

Concentration

10mM

Purity

98.92

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

NC1=NN=C(S1)SC2=NC=C([N+]([O-])=O)S2

Molecular Formula

C5H3N5O2S3

Molecular Weight

261.30

Precautions

H315, H319

References & Citations

[1]De SK, et al. Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase. J Med Chem. 2009 Apr 9;52 (7) :1943-52.|[2]Augustine C, et al. Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro. Neuroscience. 2014 Aug 22;274:1-10.|[3]Serizawa F, et al. Pretreatment of human cerebrovascular endothelial cells with CO-releasing molecule-3 interferes with JNK/AP-1 signaling and suppresses LPS-induced proadhesive phenotype. Microcirculation. 2015 Jan;22 (1) :28-36.